Tumor News and Research

RSS

New cancer panel holds promise in detection of previously undetected viral, cancer mutations

Researchers from Sanford Health and Chronix Biomedical today announced that results from a pilot study demonstrating the utility of a new cancer panel to detect previously undetected viral and cancer mutations are to be reported in a poster presentation titled "Detection of novel HPV mutations and chromosomal number imbalance (CNI) in oropharyngeal and laryngeal cancer using next-generation sequencing (NGS)" (Abstract #6072) at the American Society of Clinical Oncology Annual Meeting (ASCO 2014) being held from May 30 through June 3, 2014 in Chicago.

31 May 2014

New data highlights molecular profiling in guiding treatment of patients with gynecologic malignancies

Caris Life Sciences®, a leading biosciences company focused on fulfilling the promise of precision medicine, announced today the presentation of clinical data from studies demonstrating the potential utility of comprehensive molecular profiling in guiding treatment of patients with gynecologic malignancies, including breast cancers and ovarian cancer.

31 May 2014

$ASCO: DelMar presents interim data from VAL-083 clinical trial in refractory GBM$

ASCO: DelMar presents interim data from VAL-083 clinical trial in refractory GBM

DelMar Pharmaceuticals, Inc. announced the presentation of interim clinical data from the company's ongoing clinical trial with VAL-083 in refractory glioblastoma multiforme (GBM) during the Central Nervous System Tumor Session at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO), which is being held at the McCormick Place Convention Center in Chicago.

31 May 2014

Eisai announces results from Phase III SELECT trial of lenvatinib evaluating PFS in patients with RR-DTC

Eisai Inc. announced today results from the Phase III SELECT trial of investigational agent lenvatinib evaluating progression-free survival (PFS) in patients with progressive radioiodine-refractory differentiated thyroid cancer (RR-DTC).

31 May 2014

Angiochem presents data on ANG1005 paclitaxel-peptide drug conjugate at 50th ASCO annual meeting

Angiochem, a clinical stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier (BBB), today announced the presentation of data for its lead drug candidate, ANG1005, a novel paclitaxel-peptide drug conjugate, at the American Society of Clinical Oncology 50th Annual Meeting in Chicago, IL.

31 May 2014

Morphogenesis announces publication of new book, Cancer Vaccines: Methods and Protocols

Drs. Michael J.P. Lawman and Patricia D. Lawman, founders of the Tampa-based biotech firm Morphogenesis Inc., announce the publication of "Cancer Vaccines: Methods and Protocols," the most definitive work to date in the promising field of cancer vaccines.

31 May 2014

Agena Bioscience expands ultrasensitive somatic mutation detection technology

Agena Bioscience, Inc., which recently acquired the Bioscience business of Sequenom, Inc., today announced expansion of the UltraSEEK™ technology, the first ultrasensitive somatic mutation detection technology for high-throughput and definitive interrogation of rare mutations that occur at less than 1% abundance in matched tissue, circulating plasma, and tumor samples.

31 May 2014

FDA grants Angiochem’s ANG1005 fast track and orphan drug designation for treatment of glioblastoma multiforme

Angiochem announced today that the Food & Drug Association (FDA) has granted both orphan drug and fast track designation to ANG1005 a novel paclitaxel-peptide drug conjugate leveraging the low density lipoprotein receptor-related protein 1 (LRP-1) pathway to cross the blood-brain barrier (BBB) and enter cancer, for the treatment of glioblastoma multiforme (GBM).

31 May 2014

Deciphera initiates altiratinib MET/TIE2/VEGFR/TRK kinase inhibitor Phase 1 trial for solid tumors

Deciphera Pharmaceuticals, a clinical stage biotechnology company focused on improved kinase inhibitor treatments for cancer, today announced the initiation of a Phase 1 clinical trial of its MET/TIE2/VEGFR2/TRK inhibitor altiratinib (DCC-2701).

31 May 2014

Angiochem commences ANG1005 Phase 2 clinical study in HER2+ breast cancer patients with brain metastases

Angiochem, a clinical stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier (BBB), today announced the initiation of a Phase 2 clinical study with ANG1005, a novel paclitaxel-peptide drug conjugate, in HER2+ breast cancer patients.

31 May 2014

Researchers analysis adjuvant chemotherapy's impact on overall survival in patients with stage III STS

Fox Chase Cancer Center researchers have carried out the first retrospective analysis of adjuvant chemotherapy's impact on overall survival in patients with stage III soft tissue sarcomas (STS), adjusted for socioeconomic status and other variables.

31 May 2014

Appistry announces agreement with PGDx to include CancerSelect panel in Appistry CloudDx

Appistry, Inc., a leading provider of tools, software, and services that bring the power of genomics to next-generation medicine, today announced an agreement with Personal Genome Diagnostics (PGDx) to include the company's CancerSelect™ panel in Appistry's recently released Appistry CloudDx™ genomics testing service.

31 May 2014

Genetic changes can predict which patient will benefit from chemotherapy before bladder cancer surgery

Three genetic changes can predict whether a patient will benefit from chemotherapy before surgery to remove bladder cancer, according to new findings presented by Fox Chase Cancer Center researchers during the 50th Annual Meeting of the American Society of Clinical Oncology.

31 May 2014

Use of chemotherapy before surgery to remove ovarian cancer has increased dramatically

The use of chemotherapy before surgery to remove ovarian cancer has increased dramatically in recent decades, particularly among certain patients, according to a new analysis from Fox Chase Cancer Center that will be presented at the 50th Annual Meeting of the American Society of Clinical Oncology.

31 May 2014

InSightec inaugurates first centers in Shanghai

InSightec Ltd, the leader in MR guided Focused Ultrasound therapy, announced that the first centers in China offering ExAblate, for non-invasive treatment of uterine fibroids, have opened in Shanghai.

30 May 2014

Researchers identify new therapeutic target for treating most common form of eye cancer

Researchers at the University of California, San Diego School of Medicine have identified a therapeutic target for treating the most common form of eye cancer in adults. They have also, in experiments with mice, been able to slow eye tumor growth with an existing FDA-approved drug.

30 May 2014

Rare type of melanoma that attacks palms, soles twice likely to recur, says NYU study

A rare type of melanoma that disproportionately attacks the palms and soles and under the nails of Asians, African-Americans, and Hispanics, who all generally have darker skins, and is not caused by sun exposure, is almost twice as likely to recur than other similar types of skin cancer, according to results of a study in 244 patients.

30 May 2014

Innovative device has potential to reduce hemorrhage, save lives

Removing a malignant tumor from the head of the pancreas is a risky and demanding operation. The surgeon must carefully navigate around the stomach, the gallbladder, the bile duct, lymph nodes, and several high-pressure blood vessels.

29 May 2014

Professor receives grant to develop noninvasive method for detecting breast cancer in excised tumors

The National Science Foundation has awarded a three-year, $388,913 grant to an electrical engineering professor at the University of Arkansas to further her work on an alternative, noninvasive method of detecting breast cancer in excised tumors in real time.

29 May 2014

Initial biopsy with epigenetic test rules out prostate cancer up to 88%

A multicenter team of researchers report that a commercial test designed to rule out the presence of genetic biomarkers of prostate cancer may be accurate enough to exclude the need for repeat prostate biopsies in many — if not most — men.

29 May 2014

Tumor News and Research

New cancer panel holds promise in detection of previously undetected viral, cancer mutations

New data highlights molecular profiling in guiding treatment of patients with gynecologic malignancies

ASCO: DelMar presents interim data from VAL-083 clinical trial in refractory GBM

Eisai announces results from Phase III SELECT trial of lenvatinib evaluating PFS in patients with RR-DTC

Angiochem presents data on ANG1005 paclitaxel-peptide drug conjugate at 50th ASCO annual meeting

Morphogenesis announces publication of new book, Cancer Vaccines: Methods and Protocols

Agena Bioscience expands ultrasensitive somatic mutation detection technology

FDA grants Angiochem’s ANG1005 fast track and orphan drug designation for treatment of glioblastoma multiforme

Deciphera initiates altiratinib MET/TIE2/VEGFR/TRK kinase inhibitor Phase 1 trial for solid tumors

Angiochem commences ANG1005 Phase 2 clinical study in HER2+ breast cancer patients with brain metastases

Researchers analysis adjuvant chemotherapy's impact on overall survival in patients with stage III STS

Appistry announces agreement with PGDx to include CancerSelect panel in Appistry CloudDx

Genetic changes can predict which patient will benefit from chemotherapy before bladder cancer surgery

Use of chemotherapy before surgery to remove ovarian cancer has increased dramatically

InSightec inaugurates first centers in Shanghai

Researchers identify new therapeutic target for treating most common form of eye cancer

Rare type of melanoma that attacks palms, soles twice likely to recur, says NYU study

Innovative device has potential to reduce hemorrhage, save lives

Professor receives grant to develop noninvasive method for detecting breast cancer in excised tumors

Initial biopsy with epigenetic test rules out prostate cancer up to 88%

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Latest News